Close Menu

NEW YORK – Arbor Biotechnologies and Lonza said on Wednesday that they have forged a licensing agreement that will provide Lonza with access to Arbor's CRISPR-based gene editing technology.

Under the terms of the deal, Basel, Switzerland-based Lonza will be able to use Arbor's technology in its bioproduction products and services. Financial terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.